Peter B. Bach is a physician, epidemiologist and author at the Sloan-Kettering Memorial Cancer Center where he is the Director of the Center for Policy and Health Outcomes. His research focuses on health policies, especially those related to Medicare, racial differences in the quality of cancer care, and lung cancer. Along with his scientific writings he is often a contributor to The New York Times and other newspapers.
Video Peter Bach
Careers and education
Bach noted the treatment of his wife Ruth for early breast cancer in a series of articles for the New York Times, and then wrote about his death from the disease in a piece for New York Magazine. Bach discusses an article about the Leonard Lopate event at WNYC.
In 2012, Bach, who is a frequent critic of medicine prices in the field of cancer, co-authored an opinion in the New York Times that outlined Memorial Sloan Kettering's decision not to offer a new cancer drug, Zaltrap, to his patients for the price of the drug. At that time, the price for Zaltrap was more than twice as high as other cancer drugs already used by hospitals to treat colorectal cancer with similar efficacy. The New York Times section by Bach is discussed in the 60 Minutes segment that highlights the rising cost of cancer drugs. Bach is seen as influential in lowering the price of Zaltrap by Sanofi producers.
In 2015, Bach released DrugAbacus, billed as an interactive tool that users can use to model the price of cancer drugs based on a number of factors, including clinical efficacy, safety and toxicity, value placed in one life year, and innovation value. This tool then allows users to compare the value generated with the price of existing drugs. In addition, Bach co-wrote a paper published in the American Medical Association where he described the possible value-based drug pricing approach in the United States.
Bach also works in areas related to racial differences in the provision of cancer treatments. Together with research collaborators, he has published evidence that black Medicare recipients with lung cancer do not receive high-quality care such as white patients. A paper in 2007 showed that care in Medicare was highly fragmented, with average beneficiaries visiting many doctors and primary care specialists. She has worked on developing lung cancer screening guidelines also developing a lung cancer risk prediction model. He has proposed a number of strategies that Medicare can link the level of payments with the health value delivered.
His lay donations have included op-eds on topics such as medical school fees, doctors changing arrangements based on market power, and why cancer screening recommendations are often not followed.
Bach holds a bachelor's degree in English and American Literature from Harvard University (1986), MD from the University of Minnesota (1992) and Master of Arts in Public Policy (1997) from the University of Chicago. He received his internal medical training at Johns Hopkins Hospital, and completed a scholarship in Lung Medicine and Critical Care at the University of Chicago and Johns Hopkins Hospital.
Maps Peter Bach
More positions
- Medicare and Medicaid Service Centers (Senior Advisor Administrator: 2005-2006)
- National Cancer Policy Forum of the Institute of Medicine (Member: 2005-present)
- Working Group at HIT for the Presidential Advisory Council on Science and Technology (PCAST) (2009-2011)
- Medical Committee Committee on Geographic Variations in Health Care Expenditures (Members: 2010-present)
- Forum Agenda Global World Health Forum on Health Technology (2012-present)
References
External links
- Profile at the Memorial Sloan-Kettering Cancer Center Department of Epidemiology and Biostatistics
- Open Mind TV Show, PBS , 4/12/21. Interview with Richard Heffner, "Are We" Spending "Money for Patient Terminal?"
- Open Mind TV Show, PBS , 4/12/28. Interview with Richard Heffner, "Are We" Wasting "Money for Terminal Patients?" (Part 2)
Source of the article : Wikipedia
0 Comments